- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01245764
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
October 19, 2018 updated by: Merck Sharp & Dohme LLC
Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa
The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa.
Data from the current study are needed in order to complement existing extensive safety data from the GARDASIL™ clinical trials program, and confirm that GARDASIL™ may be administered safely and will induce immune responses in populations from and living in Sub-Saharan Africa, as GARDASIL™ has not previously been studied in this region of the world.
Study Overview
Status
Completed
Conditions
Detailed Description
In Phase A of the study, healthy females between 9 and 12 years of age will be randomized (4:1) to receive the 3-dose regimen of GARDASIL™ or placebo, and those between 13 and 26 years old will receive GARDASIL™.
In Phase B of the study, participants who received placebo in Phase A will have the option to receive the 3-dose regimen of GARDASIL™.
Study Type
Interventional
Enrollment (Actual)
250
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
9 years to 26 years (ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria :
- Healthy subjects who are native to and living in a participating Sub-Saharan African country.
- Subject agrees to provide study personnel with a primary telephone number as well as an alternate telephone number for follow-up purposes. If potential subject does not have a telephone number, the subject must provide an address at which he or she may be contacted.
- Post-pubertal female subjects must not be pregnant
- Subjects who are sexually active must agree to use effective contraception or remain abstinent through Month 7 of the study.
- Subjects who have not yet had sexual intercourse must either agree to remain abstinent through Month 7 of the study, or if they become sexually active during the vaccination phase of the study, to use effective contraception through Month 7.
- Subjects who have had sexual intercourse in the two weeks prior to enrollment must have been using effective contraception as defined above. (Emergency contraception is not considered effective contraception for enrollment in the study.)
Exclusion Criteria :
- Subject is pregnant as determined by a positive pregnancy test
- Subject has had a temperature ≥ 37.8 °C or ≥ 100 °F within 24 hours prior to the first injection.
- Subject is currently enrolled in another clinical study of an investigational agent or agents.
- Subject has a history of known prior vaccination with a HPV vaccine, or was previously enrolled in an HPV vaccine study and received either active agent or placebo.
- Subject has received any inactivated vaccine within 14 days prior to enrollment or any live vaccine within 21 days prior to enrollment.
- Subject has a history of severe allergic reaction to any agent (e.g., swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention.
- Subject has known allergy to any vaccine component, including aluminum, yeast or BENZONASE™ (nuclease, Nycomed™ [used to remove residual nucleic acids from this and other vaccines]).
- Subject has received any immune globulin preparation or blood-derived products within the 6 months prior to the first injection, or plans to receive any such products during the course of the study.
- Subject has a history of splenectomy, known autoimmune disorder (e.g., systemic lupus erythematosus, rheumatoid arthritis), or is receiving immunosuppressives (e.g., substances or treatments known to diminish immune response such as radiation therapy, administration of antimetabolites, antilymphocytic sera, systemic corticosteroids). Individuals who have received periodic treatments with immunosuppressives, defined as at least 3 courses of systemic corticosteroids each lasting at least 1 week in duration for the year prior to enrollment, will be excluded. Subjects using topical steroids (i.e., inhaled or nasal) will be eligible for vaccination.
- Subject is immunocompromised or has been diagnosed as having Human Immunodeficiency Virus (HIV) infection
- Subject has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- Subject has known sickle cell anemia disease, active malaria or active tuberculosis.
- Subject has any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives.
- Subject has a history of recent or ongoing alcohol or other drug abuse.
- Female subject has a prior history of abnormal Pap test showing squamous intraepithelial lesion (SIL), atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells, cannot rule out a high grade lesion (ASC-H), or biopsy showing cervical intraepithelial neoplasia (CIN) or worse.
- Subject has any prior history (or at Day 1) of genital warts or treatment for genital warts.
- Subject with >4 lifetime sexual partners.
- Subject has undergone hysterectomy with removal of the cervix.
- Subject plans to permanently relocate from the area prior to the completion of the study or to leave for an extended period of time when study visits would need to be scheduled.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: GARDASIL™ 9 to 12 Years Old
GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
|
|
EXPERIMENTAL: GARDASIL™ 13 to 15 Years Old
GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
|
|
EXPERIMENTAL: GARDASIL™ 16 to 26 Years Old
GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
|
|
PLACEBO_COMPARATOR: Placebo 9 to 12 Years Old
Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. After database lock and unblinding for study Phase A, participants will have the option to receive GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase B.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Seroconvert to Human Papillomavirus (HPV) Type 6
Time Frame: Month 7 (1 month postdose 3 in study Phase A)
|
Seroconversion was defined as achieving an anti-HPV Type 6 competitive Luminex Immunoassay (cLIA) level of >=20 milli Merck U/mL.
The dilution-corrected limit of detection for the Type 6 cLIA was 4.2 milli Merck U/mL.
|
Month 7 (1 month postdose 3 in study Phase A)
|
Number of Participants Who Seroconvert to HPV Type 11
Time Frame: Month 7 (1 month postdose 3 in study Phase A)
|
Seroconversion was defined as achieving an anti-HPV Type 11 cLIA level of >=16 milli Merck U/mL.
The dilution-corrected limit of detection for the Type 11 cLIA was 3.9 milli Merck U/mL.
|
Month 7 (1 month postdose 3 in study Phase A)
|
Number of Participants Who Seroconvert to HPV Type 16
Time Frame: Month 7 (1 month postdose 3 in study Phase A)
|
Seroconversion was defined as achieving an anti-HPV Type 16 cLIA level of >=20 milli Merck U/mL.
The dilution-corrected limit of detection for the Type 16 cLIA was 9.7 milli Merck U/mL.
|
Month 7 (1 month postdose 3 in study Phase A)
|
Number of Participants Who Seroconvert to HPV Type 18
Time Frame: Month 7 (1 month postdose 3 in study Phase A)
|
Seroconversion was defined as achieving an anti-HPV Type 18 cLIA level of >=24 milli Merck U/mL.
The dilution-corrected limit of detection for the Type 18 cLIA was 5.8 milli Merck U/mL.
|
Month 7 (1 month postdose 3 in study Phase A)
|
Number of Participants With Injection-site Adverse Experiences
Time Frame: Up to Day 5 after any vaccination in study Phase A
|
Participants were prompted to report injection-site experiences of pain, erythema, or swelling and were also asked to report any other injection-site adverse experiences
|
Up to Day 5 after any vaccination in study Phase A
|
Number of Participants With Elevated Temperature (Oral Temperature >=100 °F)
Time Frame: Up to Day 5 after any vaccination in study Phase A
|
Up to Day 5 after any vaccination in study Phase A
|
|
Number of Participants With Serious Adverse Experiences
Time Frame: From the time of informed consent is signed through the last study visit (up to 19 months)
|
A serious adverse experience is any adverse experience that results in death, is life threatening, results in persistent or significant disability/incapacity, results in or prolongs existing inpatient hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is another important medical event that may jeopardize the participant and may require medical or surgical intervention
|
From the time of informed consent is signed through the last study visit (up to 19 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric Mean Titer (GMT) of Anti-HPV Type 6 Antibody
Time Frame: Month 7 (1 month postdose 3 in study Phase A)
|
Anti-HPV Type 6 antibodies were measured by cLIA.
The seropositive cut-off threshold for this assay is defined as 20 milli Merck U/mL.
|
Month 7 (1 month postdose 3 in study Phase A)
|
GMT of Anti-HPV Type 11 Antibody
Time Frame: Month 7 (1 month postdose 3 in study Phase A)
|
Anti-HPV Type 11 antibodies were measured by cLIA.
The seropositive cut-off threshold for this assay is defined as 16 milli Merck U/mL.
|
Month 7 (1 month postdose 3 in study Phase A)
|
GMT of Anti-HPV Type 16 Antibody
Time Frame: Month 7 (1 month postdose 3 in study Phase A)
|
Anti-HPV Type 16 antibodies were measured by cLIA.
The seropositive cut-off threshold for this assay is defined as 20 milli Merck U/mL.
|
Month 7 (1 month postdose 3 in study Phase A)
|
GMT of Anti-HPV Type 18 Antibody
Time Frame: Month 7 (1 month postdose 3 in study Phase A)
|
Anti-HPV Type 18 antibodies were measured by cLIA.
The seropositive cut-off threshold for this assay is defined as 24 milli Merck U/mL.
|
Month 7 (1 month postdose 3 in study Phase A)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 21, 2011
Primary Completion (ACTUAL)
April 15, 2013
Study Completion (ACTUAL)
April 15, 2013
Study Registration Dates
First Submitted
November 19, 2010
First Submitted That Met QC Criteria
November 19, 2010
First Posted (ESTIMATE)
November 22, 2010
Study Record Updates
Last Update Posted (ACTUAL)
November 14, 2018
Last Update Submitted That Met QC Criteria
October 19, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V501-046
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Papillomavirus Infections
-
The AlfredMerck Sharp & Dohme LLCCompletedHuman Papillomavirus Infection | Human PapillomavirusAustralia
-
CHU de Quebec-Universite LavalCentre hospitalier de l'Université de Montréal (CHUM); Institut National en... and other collaboratorsCompletedHuman Papillomavirus InfectionsCanada
-
Kanazawa Medical UniversityMerck Sharp & Dohme LLCUnknownPapillomavirus Infections | Papillomavirus Vaccines
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention; American Cancer Society, Inc.; New... and other collaboratorsWithdrawnHuman Papillomavirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedHuman Papillomavirus Infection
-
Sanford HealthCompletedHuman Papillomavirus InfectionUnited States
-
GlaxoSmithKlineCompletedHuman Papillomavirus InfectionBahrain
-
Centre Hospitalier Universitaire de BesanconCompletedHuman Papillomavirus InfectionFrance
-
University Hospital, GenevaCompletedHuman Papillomavirus InfectionSwitzerland
-
University of ConnecticutCompletedHuman Papillomavirus Infection
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States